Abstract
DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Current Molecular Medicine
Title: Dendritic Cells and their Receptors in Antitumor Immune Response
Volume: 9 Issue: 6
Author(s): Raghvendra M. Srivastava and Ashok Khar
Affiliation:
Keywords: Dendritic cell receptors, antitumor response, apoptosis, tumor therapy
Abstract: DCs are recognized as the pivotal group of lymphocytes, which induce a variety of antitumor immune responses. Enduring professional antigen presenting cells, DCs eminence to induce adaptive antitumor immune response was exploited, which showed promising results in DCs-based phased clinical studies. Nevertheless, DCs also influence other immune cells to induce multiple arms of immune system to cure cancer. Recently, direct cytotoxic capacity of DCs has been demonstrated in several studies. Altogether DCs hold a strong link between innate and adaptive immune responses. DCs are known to kill tumor cells, phagocytose immunogenic substrates and present a wide variety of antigens to prime T cells to induce concerted antitumor responses. These functional aspects of DCs are dependent on the receptors that participate in the stimulation of DCs. In this review, we have discussed these receptors that are known to induce direct cytotoxicity as well as the receptors that greatly influence their antigen presentation functions. Thus DCs are turning out to be an important cell type in cancer immunotherapy.
Export Options
About this article
Cite this article as:
Srivastava M. Raghvendra and Khar Ashok, Dendritic Cells and their Receptors in Antitumor Immune Response, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970715
DOI https://dx.doi.org/10.2174/156652409788970715 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in Copper Radiopharmaceuticals
Current Radiopharmaceuticals Guanylate Cyclase C: A Current Hot Target, from Physiology to Pathology
Current Medicinal Chemistry Fibroblast Activation Protein in Remodeling Tissues
Current Molecular Medicine Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Mechanisms of Trastuzumab Resistance in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Inhibition of Angiogenesis by Non-Steroidal Anti-Inflammatory Drugs: From the Bench to the Bedside and Back
Current Drug Targets - Inflammation & Allergy Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy Editorial (Thematic Issue Recent Advances in Developmental Signaling Pathway Inhibitors for the Treatment of Cancer)
Current Medicinal Chemistry Midkine: A Promising Molecule for Drug Development to Treat Diseases of the Central Nervous System
Current Pharmaceutical Design The Role of Aromatase Enzyme in Hormone Related Diseases and Plant- Based Aromatase Inhibitors as Therapeutic Regimens
Current Topics in Medicinal Chemistry Application and Future Prospect of Extracellular Matrix Targeted Nanomaterials in Tumor Theranostics
Current Drug Targets Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Hypothalamic mTOR: The Rookie Energy Sensor
Current Molecular Medicine Hypoxia Inducible Factor-1 in Cancer Immune Suppression
Current Immunology Reviews (Discontinued) Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery GLUT4 Goes Abnormal: Disregulation of the Insulin-Responsive Glucose Transporter in Abnormal Metabolic States
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
Current Drug Targets Classical Inhibitors of NOX NAD(P)H Oxidases Are Not Specific
Current Drug Metabolism Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Current Topics in Medicinal Chemistry Regulation of Endothelial Cell Death and Its Role in Angiogenesis and Vascular Regression
Current Neurovascular Research